UK-based Gyroscope Therapeutics announced Nov. 8 that France’s Sanofi had committed to invest up to $60 million in equity in Gyroscope. Sanofi will invest $40 million initially, at a premium to Gyroscope’s prior Series C financing, and the remaining $20 million will be contingent on a future qualifying investment round and subject to certain closing conditions. Under the agreement, a …
EyeGate Pharmaceuticals Closes Acquisition of Bayon Therapeutics
EyeGate Pharmaceuticals announced that it has completed the planned acquisition of Bayon Therapeutics and has appointed Eric J. Daniels, MD, MBA, as its Chief Development Officer, effective as of October 21, 2021. Dr. Daniels will drive ongoing development of EyeGate’s pipeline of novel treatments for eye disease. This includes overseeing the development of a potential vision-restoring small molecule from Bayon, B-203, which …
Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDA
In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device combination product. Eyenovia will provide additional information to the FDA, as requested in the CRL, as soon as possible, including information necessary to meet additional requirements under Genus Medical …
US FDA Clears IND for 4DMT’s Wet AMD Gene Therapy Candidate
4D Molecular Therapeutics announced Oct. 6 that the US FDA had cleared the investigational new drug application (IND) for 4D-150 for wet age-related macular degeneration (wet AMD). 4D-150 is a dual-transgene intravitreal gene therapy that targets four distinct angiogenic factors, which 4DMT says has the potential for broad and durable efficacy after a single intravitreal administration in patients with wet …
Oertli Instrumente Acquires Majority Interest in Ophthalmic Instrument Maker Domedics AG
Oertli Instrumente announced it has acquired the majority of shares of Dattwil, Switzerland-based Domedics AG. Terms of the deal were not disclosed.https://eyewire.news/news/oertli-instrumente-acquires-majority-interest-in-ophthalmic-instrument-maker-domedics-ag
Adverum Presents Data Showing Gene Therapy Maintained Efficacy, Durability, Safety in Wet AMD Patients
Adverum Biotechnologies announced new long-term data from the OPTIC clinical trial of ADVM-022 single, in-office intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). Safety and efficacy data from patients followed through 2 years post injection are being presented at the Retina Society’s 54th Annual Scientific Meeting in Chicago. The presentation is available on …
BVI Announces Investment and Collaboration with Beyeonics Vision
BVI announced an investment in augmented reality company Beyeonics Vision, a medical technology subsidiary of Elbit Systems Ltd.Terms of the deal were not disclosed.Beyeonics Vision uses integrated augmented reality, tracking, and image processing/AI platforms to deliver improved visualization, optimized workflow, and real-time support to surgeon decision-making process in the operating room, according to a company news release. The collaboration is …
Eyevensys Enters Collaboration with Phillips-Medisize and Minnetronix Medical
Eyevensys has entered into strategic engagements with US-based medical device manufacturers Phillips-Medisize and Minnetronix Medical to develop the next generation of the company’s core technology. Terms of the deal were not diclosed. Eyevensys has developed a non-viral gene therapy ocular drug delivery platform with a proprietary Electrotransfection System designed to deliver DNA plasmids encoding therapeutic proteins into the ciliary muscle and sustainably treat major eye diseases. …
Novartis Acquires Arctos Medical, Expanding Optogenetic Gene Therapy Pipeline
Swiss company Novartis announced Sept. 21 that it had acquired Arctos Medical, developer of a potential optogenetic AAV gene therapy for inherited retinal disease. Financial details were not disclosed. The move comes a year after Novartis paid $150 million up front and a potential $130 million in milestone payments in September 2020 for Vedere Bio of Cambridge, Massachusetts.
Diagnostic Device Makers Luneau, Optovue Announce Merger
Ophthalmic diagnostic device manufacturers Luneau Technology, of France, and Optovue, of Fremont, California, have announced an agreement to merge. Terms of the deal were not disclosed. The companies said their combined power will allow them to leverage their industry expertise, strengthen their international footprint, and provide customers with a full product range.
